First Cystic Fibrosis Patients in U.S. Arm of Phase 2a Clinical Trial Receive RPL554

https://cysticfibrosisnewstoday.com/2017/06/08/cystic-fibrosis-patients-in-american-arm-of-phase-2a-trial-begin-receiving-rpl554/?utm_source=Cystic+Fibrosis&utm_campaign=64d2239573-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b075749015-64d2239573-71418393

Cystic fibrosis patients in the United States have begun receiving the anti-inflammatory and airway-opening agent RPL554 in a Phase 2a clinical Continue reading First Cystic Fibrosis Patients in U.S. Arm of Phase 2a Clinical Trial Receive RPL554

GlaxoSmithKline recalls nearly 600,000 albuterol inhalers

https://www.mdlinx.com/pharmacy/medical-news-article/2017/04/17/7131165/?news_id=980&newsdt=041717&subspec_id=587&utm_source=DailyNL&utm_medium=newsletter&utm_content=General-Article&utm_campaign=article-section&category=latest&page_id=1

The three affected lot numbers are 6ZP9848, 6ZP0003, and 6ZP9944. GlaxoSmithKline is voluntarily recalling 593,088 Ventolin HFA 200D albuterol Continue reading GlaxoSmithKline recalls nearly 600,000 albuterol inhalers

Capsugel and Pulmatrix Enter Collaboration to Develop and Manufacture Novel Inhaled Therapeutics

Capsugel and Pulmatrix, Inc. (“Pulmatrix”) (PULM) have formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE™-based inhaled Continue reading Capsugel and Pulmatrix Enter Collaboration to Develop and Manufacture Novel Inhaled Therapeutics

GlaxoSmithKline Recalls Ventolin HFA Albuterol Sulfate Inhalers

GlaxoSmithKline voluntary recall of Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations

Product Description Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Rx Only, For Oral Inhalation Only, Net Wt. 18 g, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0173-0682-20
Recall Number D-0519-2016
Classification Class II
Code Info Lot #s: 5ZP1708, Exp. 12/2016; 5ZP1951, Exp. 02/2017
Product Distributed Qty 128,704 Inhalers
Reason For Recall Defective Delivery System: Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.

Continue reading GlaxoSmithKline Recalls Ventolin HFA Albuterol Sulfate Inhalers